CytoDyn (OTCMKTS:CYDY – Get Free Report) will likely be issuing its Q1 2027 resultson Thursday, October 8th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Wednesday, October 14, 2026 at 9:30 AM ET.
CytoDyn Price Performance
Shares of CYDY stock opened at $0.20 on Wednesday. The firm’s 50-day moving average is $0.20 and its two-hundred day moving average is $0.26. CytoDyn has a 12 month low of $0.18 and a 12 month high of $0.40. The company has a market capitalization of $293.90 million, a PE ratio of -10.00 and a beta of 1.50.
CytoDyn Company Profile
CytoDyn Inc is a biotechnology company focused on the development of leronlimab, an investigational monoclonal antibody that targets CCR5, a receptor involved in immune-cell signaling and the movement of certain cells through the body. The company’s research has explored potential applications in infectious diseases, oncology and inflammatory conditions.
Leronlimab, also known as PRO 140, has been studied primarily as a potential treatment for HIV infection, including in combination with existing antiretroviral therapies.
Read More
- Five stocks we like better than CytoDyn
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
